Drug Trial Radar · NCT07298044
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Feb 13, 2026
Primary completion
Sep 17, 2027
Study completion Sep 17, 2027
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid. TTR amyloid gets deposited in the heart wall and stops it from pumping blood properly, which may lead to heart failure. The breakage in TTR protein can be age-related (wild-type ATTR-CM), or genetic (variant ATTR-CM). The study drug, acoramidis, works by attaching itself to the TTR protein, making TTR more stable and less likely to break down and form amyloid (clumps). This helps to slow down the progression of the disease, improve heart function, and increase the TTR levels in the blood. Acoramidis is an approved treatment for wild-type or variant ATTR-CM in Europe and the United States. Tafamidis is another drug that stabilizes TTR and prevents it from breaking down. In this study, acoramidis will be studied in participants with ATTR--CM who were previously treated with tafamidis. The main purpose of this study is to assess the change in blood TTR levels after participants are switched from tafamidis to acoramidis. This will be studied to understand if acoramidis causes an increase in blood TTR levels beyond the levels achieved with tafamidis. For this, the researchers will measure the change in the levels of TTR protein in participants' blood after 6 months of the treatment with acoramidis, or earlier if a participant stops the treatment before reaching that six-month mark. All participants will continue taking tafamidis during the screening period. In the treatment period of the study, participants will take acoramidis as two tablets twice daily by mouth, for up to 6 months. At the start of this study, the study doctors will review each participant's medical history and check their overall health. The study doctors will perform electrocardiograms (ECG), and measure blood pressure and heart rate. Researchers will also take blood and urine samples from the participants to measure levels of TTr, NT-proBNP, hs-TnT, hs-CRP, RBP4, eGFR, creatinine, cystatin-C, UACR, and TSH at the start of the study, and at various time points thereafter (during the study) to assess heart, kidney and thyroid function. There will be a total of 9 study check-ins. Participants will visit the study site twice: at screening and at the end of treatment period. A study nurse will visit the participant's home 6 times, at the start of treatment, Weeks 1, 2, 3 and 4, then again at 3 months. The final check-in will be done by phone. The study doctors will monitor the health of the participants regularly for any medical problems during follow-up visits. Participants will know the treatment they will receive during the study. Each participant could be in the study for about 8 months.
Conditions
- Transthyretin Amyloid Cardiomyopathy
Interventions
AcoramidisDrug
356 mg film-coated tablets. The recommended dose of acoramidis is 712 mg (two tablets, 356 mg) orally, twice daily, corresponding to a total daily dose of 1424 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in serum TTR level from baseline to month 6 or premature discontinuation of treatmentTime frame: From baseline to month 6 or premature discontinuation of treatment
Locations
26 sites in 5 countries. Site status is shown where the registry gives one.
Universitätsklinikum St. Pölten - Lilienfeld - Klinische Abteilung für Innere Medizin 3
Sankt Pölten, Lower Austria, Austria · Withdrawn
Medizinische Universität Wien- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie
Vienna, State of Vienna, Austria · Recruiting
Klinik Favoriten - 5.Medizinische Abteilung-Kardiologie
Vienna, State of Vienna, Austria · Recruiting
Klinik Ottakring - 3. Medizinische Abteilung mit Kardiologie, internistischer Intensivmedizin und Ambulanz
Vienna, State of Vienna, Austria · Not yet recruiting
Medizinische Universität Graz- Klinische Abteilung für Kardiologie
Vienna, Styria, Austria · Recruiting
Krankenhaus St. Josef Braunau | Innere Medizin I
Braunau am Inn, Upper Austria, Austria · Recruiting
VIVIT - Landeskrankenhaus Feldkirch - Innere Medizin I, Kardiologie, Angiologie, Endokrinologie, Diabetologie, Intensivmedizin
Feldkirch, Vorarlberg, Austria · Withdrawn
Hôpital Erasme/Erasmus Ziekenhuis
Brussels, Brussels Capital, Belgium · Not yet recruiting
AZ St-Jan Brugge-Oostende A.V.
Bruges, West Flanders, Belgium · Recruiting
Sana Klinikum Lichtenberg - Klinik für Innere Medizin II, Schwerpunkt Kardiologie
Berlin, Germany · Withdrawn
Universitätsklinikum Hamburg Eppendorf (UKE)-Universitären Herz- und Gefäßzentrum Hamburg, Klinik für Kardiologie
Hamburg, Germany · Withdrawn
Universitaetsklinikum Ulm | Klinik fuer Innere Medizin II
Ulm, Baden-Wurttemberg, Germany · Withdrawn
KVZ Kardiovaskulaeres Zentrum Darmstadt GmbH
Darmstadt, Hesse, Germany · Not yet recruiting
Universitaetsmedizin Greifswald KöR- Klinik und Poliklinik für Innere Medizin B
Greifswald, Mecklenburg-Vorpommern, Germany · Withdrawn
Universitätsklinikum Bonn - Herzzentrum des Universitätsklinikums Bonn
Bonn, North Rhine-Westphalia, Germany · Withdrawn
Azienda Ospedaliera Dei Colli_Monaldi - Malattie Rare e Genetiche Cardiovascolari
Naples, Italy · Not yet recruiting
Ospedale Vito Fazzi Lecce_Cardiologia e UTIC
Lecce, Apulia, Italy · Not yet recruiting
Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola_Cardiologia
Bologna, Emilia-Romagna, Italy · Recruiting
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Cardiologia 1
Bergamo, Lombardy, Italy · Recruiting
Centro Cardiologico Monzino S.p.A. - Cardiologia Peri-Operatoria e Imaging Cardiovascolare
Milan, Lombardy, Italy · Recruiting
Fondazione IRCCS Policlinico San Matteo-SC Medicina Generale 2 - Centro Amiloidosi Sistemiche e Malattie ad Alta Complessità
Pavia, Lombardy, Italy · Not yet recruiting
Careggi University Hospital_cardio intensive care unit
Florence, Tuscany, Italy · Recruiting
Fondazione Toscana Gabriele Monasterio_Pisa - Cardiologia e Medicina Cardiovascolare
Pisa, Tuscany, Italy · Recruiting
Azienda Ospedaliera Universitaria Senese - cardiologia
Siena, Tuscany, Italy · Recruiting
Azienda Ospedale-Università di Padova-UOC Cardiologia
Padova, Veneto, Italy · Recruiting
Oslo Universitetssykehus HF, Rikshospitalet
Oslo, Norway · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.